Unitaid Official Discusses HIV Treatment Pricing Deal In Intellectual Property Watch Interview

Intellectual Property Watch: Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest
“…In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the U.N. and foundations announced what they called a breakthrough pricing agreement that will speed the availability of ‘the first affordable, generic, single-pill HIV treatment regimen containing (the key compound) dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year.’ … In an interview with Intellectual Property Watch after the press conference, Unitaid’s Philippe Duneton explained in detail how the agreement came into being and why it is so important…” (New, 9/25).